Andrey Golanov

Andrey Golanov


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
RKRahul Kumar
Rahul Kumar
KSKyle S. Smith
Kyle S. Smith
MDMaximilian Deng
Maximilian Deng
CTColt Terhune
Colt Terhune
GRGiles Robinson
Giles Robinson
PNPaul A. Northcott
Paul A. Northcott
PURPOSE: We sought to investigate clinical outcomes of relapsed medulloblastoma and to compare molecular features between patient-matched diagnostic and relapsed tumors. METHODS: Children and infants enrolled on either SJMB03 (NCT00085202) or SJYC07 (NCT00602667) trials who experienced medulloblastoma relapse were analyzed for clinical outcomes, including anatomic and temporal patterns of relapse and postrelapse survival. A largely independent, paired molecular cohort was analyzed by DNA methylation array and next-generation sequencing. RESULTS: A total of 72 of 329 (22%) SJMB03 and 52 of 79 (66%) SJYC07 patients experienced relapse with significant representation of Group 3 and wingless tumors. Although most patients exhibited some distal disease (79%), 38% of patients with sonic hedgehog tumors experienced isolated local relapse. Time to relapse and postrelapse survival varied by molecular subgroup with longer latencies for patients with Group 4 tumors. Postrelapse radiation therapy among previously nonirradiated SJYC07 patients was associated with long-term survival. Reirradiation was only temporizing for SJMB03 patients. Among 127 patients with patient-matched tumor pairs, 9 (7%) experienced subsequent nonmedulloblastoma CNS malignancies. Subgroup (96%) and subtype (80%) stabilities were largely maintained among the remainder. Rare subgroup divergence was observed from Group 4 to Group 3 tumors, which is coincident with genetic alterations involving MYC, MYCN, and FBXW7. Subgroup-specific patterns of alteration were identified for driver genes and chromosome arms. CONCLUSION: Clinical behavior of relapsed medulloblastoma must be contextualized in terms of up-front therapies and molecular classifications. Group 4 tumors exhibit slower biological progression. Utility of radiation at relapse is dependent on patient age and prior treatments. Degree and patterns of molecular conservation at relapse vary by subgroup. Relapse tissue enables verification of molecular targets and identification of occult secondary malignancies.

13 February 2021 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
BSBoris Shirokikh
Boris Shirokikh
ASAlexey Shevtsov
Alexey Shevtsov
ADAlexandra Dalechina
Alexandra Dalechina
EKEgor Krivov
Egor Krivov
VKValery Kostjuchenko
Valery Kostjuchenko
MBMikhail Belyaev
Mikhail Belyaev
The prevailing approach for three-dimensional (3D) medical image segmentation is to use convolutional networks. Recently, deep learning methods have achieved human-level performance in several important applied problems, such as volumetry for lung-cancer diagnosis or delineation for radiation therapy planning. However, state-of-the-art architectures, such as U-Net and DeepMedic, are computationally heavy and require workstations accelerated with graphics processing units for fast inference. However, scarce research has been conducted concerning enabling fast central processing unit computations for such networks. Our paper fills this gap. We propose a new segmentation method with a human-like technique to segment a 3D study. First, we analyze the image at a small scale to identify areas of interest and then process only relevant feature-map patches. Our method not only reduces the inference time from 10 min to 15 s but also preserves state-of-the-art segmentation quality, as we illustrate in the set of experiments with two large datasets.

1 September 2002 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
Andrey KorshunovAndrey Korshunov
Andrey Korshunov
LSLyudmila Shishkina
Lyudmila Shishkina
AGAndrey Golanov
Andrey Golanov
Routine pathologic examination cannot distinctively predict the clinical course of meningiomas because even histologically benign tumors may recur after gross total resection. Therefore, numerous efforts have been made to evaluate the meningioma growth fraction and its prognostic value. However, a universally applicable proliferative marker for meningioma outcome is not yet a reality. To investigate the prognostic utility of 3 proliferative markers, namely, Ki-67, DNA topoisomerase II-alpha (topoII), and cyclin A in a representative series of intracranial meningiomas. Two hundred sixty-three adult patients with intracranial meningiomas (208 benign, 42 atypical, and 13 anaplastic) were studied retrospectively. Tumor specimens were immunohistochemically examined with antibodies to Ki-67 (MM-1), topoII, and cyclin A. A computerized color image analyzer was used to count immunostained nuclei. The topoII and cyclin A scores exhibited a close correlation with Ki-67 immunostaining. Significant differences between the indices for all 3 markers were noted among the 3 grades of meningiomas. The scores for all 3 markers were significantly different between recurrent and nonrecurrent meningiomas, including benign tumors that were treated with gross total resection. Recurrence-free survival was significantly reduced for cases with a Ki-67 labeling index (LI) of 4.4% or greater, a topoII LI of 3.2% or greater, and a cyclin A LI of 3.1% or greater. Multivariate analysis revealed that the risk of recurrence for the entire meningioma cohort was significantly associated with tumor grade (hazard ratio = 2.7; P =.004), topoII LI of 3.2% or greater (hazard ratio = 5.5; P <.001), and a cyclin A LI of 3.1% or greater (hazard ratio = 2.4; P =.01). There is a close correlation in the expression of these 3 proliferative markers in meningiomas, and all of the markers showed a significant association with tumor grade, recurrence rate, and recurrence-free survival. Consequently, in addition to Ki-67, immunoexpression of topoII and cyclin A is available for predicting meningioma recurrence. Moreover, the topoII and cyclin A staining scores were found to be more sensitive predictors for meningioma progression than Ki-67 and, therefore, either of these 2 markers may prove to be clinically informative and useful.

6 July 2021 in Surgical Neurology International
Verified
Journal Article
Open access
AKAnton Konovalov
Anton Konovalov
SMSergey Maryashev
Sergey Maryashev
DPDavid Pitskhelauri
David Pitskhelauri
VSVitaly Siomin
Vitaly Siomin
AGAndrey Golanov
Andrey Golanov
ADAleksandra Dalechina
Aleksandra Dalechina
Background: The purpose of the presented work is to evaluate the last decade’s experience in surgical management of central neurocytoma (CN) and elucidate on the treatment strategies and new options. Methods: The current series consists of the remaining 125 patients (70 females and 55 males) operated on during the past decade from 2008 to 2018. Most tumors were resected through transcortical (n = 76, 61%), or transcallosal (n = 40, 32%) approaches. In 5 (4%) patients with predominantly posterior location of the tumor, non-dominant superior parietal lobule approach was utilized. Both approaches (transcortical + transcallosal) were used in 4 (3%) of cases. Seven consecutive patients with large CN underwent prophylactic intraventricular stenting to prevent hydrocephalus. Results: Gross total resection was achieved in 45 patients (36%), subtotal resection (STR) in 40 (32%) cases. After surgery, 63 (50%) patients had neurocognitive problems, including disorientation, attention deficit, global amnesia, short-term memory deficits, and perceptual motor and social cognition problems. A total of 26 patients (21%) had postoperative hemorrhage in the resection bed. Obstructive hydrocephalus was noted in 25 (20%) patients. The entrapment of the occipital and/or temporal horns was observed in seven cases. None of the seven patients with prophylactic intraventricular stents required shunting. Conclusion: Although high rates of gross total or STR can be expected, the mortality and morbidity remain significant even in the modern neurosurgical era. Prophylactic intraventricular stenting in patients with large posteriorly located tumors with hydrocephalus may prevent ventricular entrapment and shunting. The main risk factors for recurrence are presence of residual disease and Ki-67 index over 5%. Recurrent symptomatic tumors should be treated surgically, whereas asymptomatic progression can be managed with stereotactic radiosurgery. Both treatment modalities are associated with low risk of complications and high tumor control rates.

1 January 2022 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
ASA.N. Savateev
A.N. Savateev
AGAndrey Golanov
Andrey Golanov
DSD.A. Saushev
D.A. Saushev
IOI.K. Osinov
I.K. Osinov
VKV.V. Kostyuchenko
V.V. Kostyuchenko
EME.S. Makashova
E.S. Makashova
Гамартома гипоталамуса (ГГ) — диспластическое объемное образование, связанное с гипоталамусом, клинически проявляющееся структурной эпилепсией и преждевременным половым развитием. Частота полного регресса эпилептических приступов после хирургического лечения составляет около 50%, но тяжелые осложнения возникают примерно у каждого четвертого из оперированных пациентов. Альтернативой прямому вмешательству являются радиочастотная термокоагуляция, лазерная аблация и стереотаксическая радиохирургия (СРХ) гамартомы. ЦЕЛЬ ИССЛЕДОВАНИЯ На основании собственного опыта уточнить анамнестические, клинические и радиохирургические параметры, влияющие на эффективность СРХ на аппарате Гамма-нож у пациентов с ГГ, определить клинический профиль пациентов-кандидатов на СРХ и оптимальные параметры облучения. МАТЕРИАЛ И МЕТОДЫ В Московском Центре «Гамма-нож» АО «Деловой центр нейрохирургии» СРХ проведена 22 пациентам со структурной эпилепсией, вызванной ГГ. В ретроспективный анализ исходов лечения включено 19 пациентов с достаточной длительностью катамнестического наблюдения. Медиана возраста пациентов на момент СРХ составила 11,5 (1,3—25,8) года. Диаметр облученных ГГ варьировал от 5,5 до 40,9 мм. Объем 8 (36%) гамартом был более 3 см3. Предписанная доза составила в среднем 18±2,0 Гр, предписанная изодоза — 48±4,2%. Медиана длительности наблюдения — 14,8 (3,4–96,1) мес. РЕЗУЛЬТАТЫ У 3 (15,8%) пациентов достигнут полный регресс приступов; у 1 (5,3%) пациента после лечения отсутствовали генерализованные приступы и сохранялись только редкие эмоциональные; у 11 (57,8%) приступы стали значительно реже. Не уменьшилась частота приступов у 4 (21,1%) пациентов. Хорошие результаты чаще удавалось достичь при средней дозе в мишени выше 20–22 Гр, минимальной дозе более 7–10 Гр, покрытии предписанной дозой не менее 70–80%, а также у пациентов с практически полным покрытием всего объема ГГ дозой выше 12 Гр. Ни у одного пациента не было осложнений после СРХ. ВЫВОДЫ Стереотаксическая радиохирургия при корректно установленных показаниях является эффективным методом лечения структурной эпилепсии, обусловленной гамартомой гипоталамуса. Метод безопасен в отношении неврологических, эндокринных, зрительных и гипоталамических функций. Оптимальными кандидатами для стереотаксической радиохирургии на аппарате Гамма-нож являются дети, у которых приступы манифестировали в возрасте старше 1 года, с гамартомой объемом менее 3 см3 и площадью ее контакта с гипоталамусом не более 150 мм2.

1 January 2021 in CLINICAL AND EXPERIMENTAL MORPHOLOGY
Verified
Journal Article
Closed access
ABA.S. Balkanov
A.S. Balkanov
IRI.D. Rozanov
I.D. Rozanov
AGAndrey Golanov
Andrey Golanov
LGL.E. Gaganov
L.E. Gaganov
VCV.P. Chernikov
V.P. Chernikov
Introduction. Despite the treatment methods’ improvement, the brain glioblastoma (GB) patient survival remains at the level of 12–14 months. In this regard, it is very relevant to optimize the choice of the treat-ment of recurrent GB, including using stereotactic radiosurgery (SRS). Materials and methods. Comparative analysis of the endothelial cells in the capillaries of blood vessels of the brain peritumoral zone (PZ) before (1 group – 32 capillaries) and 12 – 14 months after (2 group – 75 capillaries) adjuvant external radiation therapy (AERT) was performed using transmission electron micros-copy (TEM). Results. Apoptosis of endotheliocytes was observed in the capillaries of the brain PZ from 2 group much more often than from 1 group (60% and 12.6% of capillaries, respectively, p<0.001). Capillary death and thrombosis occurred in 4% and 1.4% of 2 group capillaries. An important finding was that only 69.3 of capillaries from 2 group revealed thickening of the basement membrane (BM), and 26.9% of them also revealed its peak deformation. Conclusion. 12–14 months after AERT, the brain PZ remains ischemic due to apoptosis of the capillary endothelium, thickening and peak deformation of the BM. The detected signs of revascularization of the brain PZ after previously performed AERT suggest that it is possible to consider SRS as a method of treat-ment for recurrent brain GB. Keywords: brain glioblastoma, peritumoral zone, endotheliocyte apoptosis, thickening of the basement membrane, stereotactic radiosurgery, glioblastoma relapse